Actinium Pharmaceuticals Inc (ATNM)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.03-1.90%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ATNM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -71.0% |
| Our one-year growth estimate | diamond | -36.1% |
Growth built into the price is above our model estimate.
The price assumes 34.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ATNM — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued
Dated 2026-08-14
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received notice from NYSE American LLC (“NYSE American”) that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide (the “Company Guide”). The Company submitted a compliance plan to NYSE American on June 18, 202…
Why it matters: Operating losses are better but still high. More improvements show better financial health.
Supportive ifOperating income improves to less than -$5 million in the next quarter.
Worry ifOperating income worsens or stays above -$5 million in the next quarter.
Why it matters: New patents will help Actinium's IP and boost future earnings from Actimab-A.
Supportive ifActinium gets new patents for Actimab-A. This expands its treatment options.
Worry ifNo new patents are granted or applications are rejected.
Why it matters: If health care sector growth picks up, it may benefit Actinium's performance. The sector is currently in a maturing phase with slowing growth.
Supportive ifHealth care sector revenue growth is speeding up again toward its past highs.
Worry ifSector revenue growth keeps slowing down. This shows more challenges ahead.
Why it matters: Ongoing losses may show financial problems. This can slow down recovery efforts.
Worry ifOperating losses in Q2 2026 are worse than -$5.9 million reported in Q1 2026.
Less concerning ifOperating losses improve to less than -$5.9 million in Q2 2026.
Why it matters: Progress in clinical trials can boost investor confidence and support future funding. Delays could hurt the stock.
Supportive ifLook for clinical data or milestones for ATNM-400 in late 2026.
Worry ifNo updates or delays in the clinical milestones for ATNM-400.
Why it matters: This report gives details about financial performance. It also shows progress on profit goals.
Watch forThe earnings report shows a big rise in net income or revenue.
Also watch forThe earnings report shows ongoing losses or no gains in financial metrics.
Why it matters: Cash flow is still negative but has shown improvement. Stability is key for financial health.
Supportive ifCash from operations turns positive in the next quarter.
Worry ifCash from operations remains negative or worsens in the next quarter.
Why it matters: New data on ATNM-400 could highlight its potential and drive interest in the stock.
Supportive ifThere is good feedback or strong interest in ATNM-400 from the SNMMI conference.
Worry ifATNM-400 gets a poor reception or bad feedback at the conference.
Why it matters: Changes in leadership can affect the company. This can hurt investor trust.
Watch forA permanent CEO or key leadership roles are announced.
Also watch forThere is more news about interim leaders or resignations.
Why it matters: Actinium got a notice for not meeting the $4 million equity rule. This affects its listing.
Worry ifActinium reports stockholders' equity of $4 million or more by the next earnings date.
Less concerning ifStockholders' equity is still below $4 million. This may lead to more delisting actions.
Why it matters: Acceptance of the compliance plan is crucial for keeping the stock listed. Failure could lead to delisting.
Supportive ifNYSE American accepts the compliance plan submitted by June 26, 2026.
Worry ifNYSE American rejects the compliance plan or the company fails to submit it.
Why it matters: Better financial results may show progress toward making money. Ongoing losses may worry investors.
Supportive ifQ3 financial results show net income or smaller losses than before.
Worry ifQ3 results show big net losses with no signs of improvement.
Why it matters: Actinium needs to meet rules to stay listed. This impacts how investors feel.
Worry ifManagement has a plan that NYSE American accepted. This shows they are making progress.
Less concerning ifThe NYSE American rejects the compliance plan or the company fails to meet deadlines.
Why it matters: Progress in clinical trials could validate Actinium's pipeline and boost stock value.
Supportive ifManagement will share good news or updates from clinical trials in 2H:2026.
Worry ifNo news or bad results from the clinical trials for ATNM-400 or Actimab-A.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$237 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $592 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,570 loss on $10,000 · 55.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.